CY1110336T1 - Χρηση της αλλοπουρινολης για τη θεραπεια της παλαμοπελματικης ερυθροδυσαισθησιας - Google Patents

Χρηση της αλλοπουρινολης για τη θεραπεια της παλαμοπελματικης ερυθροδυσαισθησιας

Info

Publication number
CY1110336T1
CY1110336T1 CY20101100279T CY101100279T CY1110336T1 CY 1110336 T1 CY1110336 T1 CY 1110336T1 CY 20101100279 T CY20101100279 T CY 20101100279T CY 101100279 T CY101100279 T CY 101100279T CY 1110336 T1 CY1110336 T1 CY 1110336T1
Authority
CY
Cyprus
Prior art keywords
treatment
palamophylatic
allopurinolis
sleep
allopurinol
Prior art date
Application number
CY20101100279T
Other languages
English (en)
Inventor
Yolanda Rodemer
Original Assignee
Nobera Pharma, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06011432A external-priority patent/EP1862166A1/en
Application filed by Nobera Pharma, S.L. filed Critical Nobera Pharma, S.L.
Publication of CY1110336T1 publication Critical patent/CY1110336T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Χρήση της αλλοπουρινόλης ή ενός φαρμακευτικά αποδεκτού άλατος αυτής για τη θεραπεία ή την πρόληψη της παλαμοπελματικής ερυθροδυσαισθησίας που προκαλείται από χημειοθεραπεία. Η αλλοπουρινόλη ή το άλας της χορηγείται τοπικά στις περιοχές που έχουν προσβληθεί, τις παλάμες και τα πέλματα, κατά προτίμηση στη μορφή μιας κρέμας.
CY20101100279T 2006-06-01 2010-03-23 Χρηση της αλλοπουρινολης για τη θεραπεια της παλαμοπελματικης ερυθροδυσαισθησιας CY1110336T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06011432A EP1862166A1 (en) 2006-06-01 2006-06-01 Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
EP07107744 2007-05-08
EP07729768A EP2035006B1 (en) 2006-06-01 2007-05-31 Use of allopurinol for the treatment of palmar plantar erythrodysesthesia

Publications (1)

Publication Number Publication Date
CY1110336T1 true CY1110336T1 (el) 2015-01-14

Family

ID=38512579

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100279T CY1110336T1 (el) 2006-06-01 2010-03-23 Χρηση της αλλοπουρινολης για τη θεραπεια της παλαμοπελματικης ερυθροδυσαισθησιας

Country Status (21)

Country Link
US (3) US7973046B2 (el)
EP (1) EP2035006B1 (el)
JP (3) JP5028480B2 (el)
KR (1) KR101471022B1 (el)
AT (1) ATE457729T1 (el)
AU (1) AU2007267069B2 (el)
CA (1) CA2654270C (el)
CY (1) CY1110336T1 (el)
DE (1) DE602007004849D1 (el)
DK (1) DK2035006T3 (el)
ES (1) ES2341379T3 (el)
HR (1) HRP20100210T1 (el)
IL (1) IL195472A (el)
MX (1) MX2008015266A (el)
NZ (1) NZ573248A (el)
PL (1) PL2035006T3 (el)
PT (1) PT2035006E (el)
RS (1) RS51252B (el)
RU (1) RU2438673C2 (el)
SI (1) SI2035006T1 (el)
WO (1) WO2007138103A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246057A1 (en) * 2009-04-29 2010-11-03 Nobera Pharma, S.L. Use of allopurinol for the treatment of hand foot skin reaction
US9220713B2 (en) 2009-10-16 2015-12-29 Duke University Compositions and methods for the treatment of drug-induced hand-foot syndrome
EP2368549A1 (en) 2010-03-25 2011-09-28 BioAlliance Pharma Treating hand-foot syndrome and related pathologies using clonidine or its derivatives
JP4761000B1 (ja) * 2010-11-08 2011-08-31 小野薬品工業株式会社 手足症候群の予防および／または治療剤
JP4983989B2 (ja) * 2010-03-31 2012-07-25 小野薬品工業株式会社 手足症候群の予防および治療剤
ES2604705T3 (es) * 2010-03-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Agente preventivo y/o remedio para el síndrome mano-pie
US9259343B2 (en) 2012-07-06 2016-02-16 Newman Technologies LLC Device for mitigating plantar fasciitis
EP2712613B1 (en) * 2012-09-28 2017-02-08 Pharmadab d.o.o. Vitamin K1 and uses thereof
CN108778263A (zh) * 2016-03-28 2018-11-09 维达克制药有限公司 用于局部用药的稳定药物组合物及其用途
JP2021506958A (ja) 2017-12-13 2021-02-22 オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． Ｅｇｆｒ阻害に関連する疾患を予防又は治療する方法
AU2019254237A1 (en) 2018-04-16 2020-12-03 Onquality Pharmaceuticals China Ltd. Method for preventing or treating side effects of cancer therapy
RU2722396C2 (ru) * 2018-07-11 2020-05-29 Федеральное государственное бюджетное учреждение дополнительного профессионального образования "Центральная государственная медицинская академия" Управления делами Президента Российской Федерации (ФГБУ ДПО "ЦГМА") Способ лечения пальмарно-плантарной эритродизестезии

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3011A (en) * 1843-03-21 Improvement in water-wheels
DE3772193D1 (de) 1987-02-13 1991-09-19 Allergan Pharma Verwendung von pteridinen und/oder purinen oder eines xanthinoxidase-hemmers zur herstellung eines arzneimittels zur behandlung von genetisch bedingten degenerativen netzhauterkrankungen.
JPH03106817A (ja) 1989-09-20 1991-05-07 Nippon Kayaku Co Ltd アロプリノール製剤
JPH066700A (ja) 1992-06-22 1994-01-14 Fujitsu General Ltd ハイビジョン受像機
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
WO1994005293A1 (en) 1992-09-04 1994-03-17 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
EP1292265B1 (de) * 2000-06-20 2007-03-21 Henkel Kommanditgesellschaft auf Aktien Verwendung von Vitamin B6-Derivaten zur Haarstrukturverbesserung
WO2002041837A2 (en) 2000-11-22 2002-05-30 Rxkinetix, Inc. Treatment of mucositis
US7544348B2 (en) 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
ATE429947T1 (de) * 2001-08-29 2009-05-15 Pharmakodex Ltd Vorrichtung zur topischen verabreichung
CN1596111A (zh) * 2001-11-29 2005-03-16 桑得医药品公司 减轻化疗引起的不良效果的组合物及方法
DE10200578A1 (de) * 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
CA2528378A1 (en) 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
AU2004247109A1 (en) 2003-06-11 2004-12-23 Novacea, Inc Treatment of cancer with active vitamin D compounds in combination with radiotherapeutic agents and treatments
US20050148908A1 (en) 2003-12-24 2005-07-07 Gregory Skover Apparatus containing a receiving element for treatment of skin
CA2557814A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
US7709524B2 (en) * 2004-09-17 2010-05-04 Biomas Ltd. Use of tellurium compounds for inhibition of interleukin-converting enzyme

Also Published As

Publication number Publication date
SI2035006T1 (sl) 2010-04-30
US7973046B2 (en) 2011-07-05
JP2009542581A (ja) 2009-12-03
IL195472A (en) 2012-04-30
ATE457729T1 (de) 2010-03-15
US8557829B2 (en) 2013-10-15
US20090306097A1 (en) 2009-12-10
DK2035006T3 (da) 2010-04-19
RS51252B (sr) 2010-12-31
NZ573248A (en) 2011-01-28
WO2007138103A1 (en) 2007-12-06
EP2035006B1 (en) 2010-02-17
AU2007267069A1 (en) 2007-12-06
IL195472A0 (en) 2011-08-01
JP2012180370A (ja) 2012-09-20
US20110224237A1 (en) 2011-09-15
HRP20100210T1 (hr) 2010-05-31
RU2438673C2 (ru) 2012-01-10
JP5028480B2 (ja) 2012-09-19
CA2654270C (en) 2014-05-13
KR20090031697A (ko) 2009-03-27
DE602007004849D1 (de) 2010-04-01
RU2008152341A (ru) 2010-07-20
AU2007267069B2 (en) 2011-08-11
KR101471022B1 (ko) 2014-12-09
PT2035006E (pt) 2010-04-22
CA2654270A1 (en) 2007-12-06
PL2035006T3 (pl) 2010-07-30
JP2014028851A (ja) 2014-02-13
US20140011820A1 (en) 2014-01-09
MX2008015266A (es) 2009-02-10
JP5389980B2 (ja) 2014-01-15
ES2341379T3 (es) 2010-06-18
EP2035006A1 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
CY1110336T1 (el) Χρηση της αλλοπουρινολης για τη θεραπεια της παλαμοπελματικης ερυθροδυσαισθησιας
EA202091303A2 (ru) Композиция ингибитора jak для местного применения
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
ECSP088902A (es) Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios
WO2009114810A3 (en) Use of ellagitannins as inhibitors of bacterial quorum sensing
CU20130069A7 (es) Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis
UY29127A1 (es) Nuevos derivados de pirimidina y su uso
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
ATE543492T1 (de) Behandlung von lungenkrebs
MX2009005798A (es) Recuperacion de apoplejia.
CR10410A (es) Carboxamidas sustituidas.
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
MX2011011529A (es) Uso de alopurinol para el tratamiento de la reaccion cutanea en manos-pies.
WO2006102899A3 (en) Oxaprozin or closely related compound for the treatment and prevention of
DK1732551T3 (da) Perhexilin til behandling af kronisk hjertesvigt
DE602005023742D1 (de) Formulierung von 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-on mit verzögerter freisetzung
BRPI0918593A2 (pt) composição farmacêutica para uso no tratamento de infecções transmitidas sexualmente
CY1114028T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια των ακροχορδωνων
CY1114601T1 (el) Χρηση της αλλοπουρινολης για την αγωγη της δερματικης αντιδρασης χειρος-ποδος
EA200970292A1 (ru) Производные 5-тиоксилопиранозы и их применение в терапии
DOP2005000177A (es) Nuevos derivados de pirimidina y su uso
MX2009004627A (es) Uso de inhibidores de dipeptidil-peptidasa iv para prevenir, demorar, o reducir la presentacion de edema.